The global antithrombin market size was estimated at USD 658.4 million in 2024 and is projected to reach USD 997.2 million by 2033, growing at a CAGR of 4.7% from 2025 to 2033. The rising prevalence of coagulation disorders such as deep vein thrombosis, pulmonary embolism, and hereditary antithrombin deficiency primarily drives the antithrombin market.
Increasing surgical procedures, trauma cases, and complications during pregnancy that elevate thrombosis risk are also contributing to higher demand for antithrombin therapy. The antithrombin industry is driven by the steady rise of thromboembolic and coagulation disorders, growing awareness of hereditary antithrombin deficiency, and the importance of early anticoagulant therapy. In the U.S, 900,000 people are affected by venous thromboembolism (VTE) each year, with individuals at particularly high risk during or just after hospitalization, cancer treatment, or pregnancy. An estimated 60,000 to 100,000 Americans die annually from VTE, while many others experience long-term complications, thus highlighting the critical need for effective prevention and management.
Increasing surgical procedures, trauma incidents, and pregnancy-related complications have further amplified the demand for antithrombin therapy. Treatment options worldwide include plasma-derived and recombinant formulations, with recombinant products gaining wider acceptance due to higher safety, purity, and reduced infection risks. The expansion of their use in critical care, cardiac surgeries, and obstetric cases, supported by advancements in biotechnology and favorable regulatory approvals, continues to propel the global antithrombin market forward.
This product will be delivered within 1-3 business days.
Increasing surgical procedures, trauma cases, and complications during pregnancy that elevate thrombosis risk are also contributing to higher demand for antithrombin therapy. The antithrombin industry is driven by the steady rise of thromboembolic and coagulation disorders, growing awareness of hereditary antithrombin deficiency, and the importance of early anticoagulant therapy. In the U.S, 900,000 people are affected by venous thromboembolism (VTE) each year, with individuals at particularly high risk during or just after hospitalization, cancer treatment, or pregnancy. An estimated 60,000 to 100,000 Americans die annually from VTE, while many others experience long-term complications, thus highlighting the critical need for effective prevention and management.
Increasing surgical procedures, trauma incidents, and pregnancy-related complications have further amplified the demand for antithrombin therapy. Treatment options worldwide include plasma-derived and recombinant formulations, with recombinant products gaining wider acceptance due to higher safety, purity, and reduced infection risks. The expansion of their use in critical care, cardiac surgeries, and obstetric cases, supported by advancements in biotechnology and favorable regulatory approvals, continues to propel the global antithrombin market forward.
Global Antithrombin Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global antithrombin market report based on application, source, type, and region:Application Outlook (Revenue, USD Million, 2021-2033)
- Therapeutics
- Diagnostics
- Research
- Other
Source Outlook (Revenue, USD Million, 2021-2033)
- Human
- Recombinant Goat Milk
- Others
Type Outlook (Revenue, USD Million, 2021-2033)
- Anticoagulant
- Antiplatelet
- Thrombolytic Drugs
Regional Outlook (Revenue, USD Million, 2021-2033)
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
Report Deliverables
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Antithrombin Market Variables, Trends & Scope
Chapter 4. Antithrombin Market: Application Estimates & Trend Analysis
Chapter 5. Antithrombin Market: Source Estimates & Trend Analysis
Chapter 6. Antithrombin Market: Type Estimates & Trend Analysis
Chapter 7. Antithrombin Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The companies profiled in this Antithrombin market report include:- CS
- Grifols, S.A.
- Takeda Pharmaceutical Company Limited.
- Octapharma AG
- LFB
- ENDPOINT HEALTH, INC.
- Siemens Healthineers AG
- Thermo Fisher Scientific Inc.
- Medix Biochemica
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | October 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 658.4 Million |
| Forecasted Market Value ( USD | $ 997.2 Million |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
